First Foundation Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

First Foundation Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Sell	519 -1	-0.2%	-$443	0.01%	315
2026 Q1	$232K	Buy	520 +5	+1%	+$2.33K	0.01%	311
2025 Q4	$233K	Hold	515	–	–	0.01%	310
2025 Q3	$202K	Hold	515	–	–	0.01%	317
2025 Q2	$229K	Buy	+515	New	+$237K	0.01%	313
2024 Q3	–	Sell	-347	Closed	-$163K	–	445
2024 Q2	$163K	Sell	347 -24	-6%	-$10.4K	0.01%	337
2024 Q1	$155K	Hold	371	–	–	0.01%	348
2023 Q4	$151K	Sell	371 -481	-56%	-$178K	0.01%	358
2023 Q3	$296K	Sell	852 -109	-11%	-$38.1K	0.01%	328
2023 Q2	$338K	Buy	961 +110	+13%	+$37.1K	0.01%	296
2023 Q1	$268K	Buy	851 +9	+1%	+$2.7K	0.01%	313
2022 Q4	$243K	Buy	+842	New	+$257K	0.01%	338

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

First Foundation Advisors's VRTX Position: Q2 2026 in Review

First Foundation Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.19% in Q2 2026, selling an estimated $443 and leaving 519 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #315.

First Foundation Advisors first reported a position in VRTX in Q4 2022 and has held it in 12 quarters since. The position peaked at $338K in Q2 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

First Foundation Advisors held 519 shares of Vertex Pharmaceuticals worth $258K as of Q2 2026.
First Foundation Advisors sold 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
Vertex Pharmaceuticals made up 0.01% of First Foundation Advisors's portfolio in Q2 2026, its #315 holding.
First Foundation Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
First Foundation Advisors's Vertex Pharmaceuticals position peaked at $338K in Q2 2023.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on First Foundation Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.